Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma - FLASH

Study identifier:D7552C00001

ClinicalTrials.gov identifier:NCT05251259

EudraCT identifier:2021-003338-35

CTIS identifier:N/A

Recruiting

Official Title

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults with Moderate to Severe Uncontrolled Asthma

Medical condition

asthma

Phase

Phase 2

Healthy volunteers

No

Study drug

Atuliflapon, Placebo

Sex

All

Estimated Enrollment

666

Study type

Interventional

Age

18 Years - 80 Years

Date

Study Start Date: 27 Jan 2022
Estimated Primary Completion Date: 29 Jan 2025
Estimated Study Completion Date: 29 Jan 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria